trending Market Intelligence /marketintelligence/en/news-insights/trending/6KkqYWhpHOJ1MhK7PDNw6w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly, Innovent's immune therapy for blood cancer gets Chinese approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lilly, Innovent's immune therapy for blood cancer gets Chinese approval

SNL Image

Eli Lilly and Co. and Innovent Biologics Inc. said their drug Tyvyt was approved in China for treating classical Hodgkin's lymphoma, a type of blood cancer.

China's National Medical Products Administration granted the nod to Tyvyt, or sintilimab, for treating patients whose classical Hodgkin's lymphoma did not respond to therapy or came back after two or more lines of systemic chemotherapy.

Tyvyt is an anti-PD-1 therapy, a cancer-targeting drug that blocks the PD-1 arm on healthy cells from linking up with a partner arm on the surface of cancer cells to spread the disease. The therapy's efficacy and safety was studied in the Orient-1 trial, Wang Li, senior vice president of Lilly China and head of Lilly China drug development and medical affairs, said in a news release.

Tyvyt is being tested in over 20 clinical trials, including studies in lung, gastric, liver and esophageal cancers.

Indianapolis-based Eli Lilly and China's Innovent Biologics are co-developing Tyvyt under a collaboration announced in March 2015. Under the deal, the companies agreed to develop and commercialize at least three cancer therapies over the next 10 years.